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TO THE EDITORTranscaval Retrograde
Transcatheter Aortic Valve
Replacement for Patients
With No Other AccessFirst-in-Man Experience With CoreValveThe ﬁrst transcatheter aortic valve replacement
(TAVR) approach was antegrade transvenous trans-
septal. This approach obligated transseptal catheter-
ization and a more circuitous path to deploy the
valve. The procedural complexities associated with
the transseptal approach led to its replacement by the
“less complex” and most commonly utilized trans-
femoral (TF) arterial retrograde approach (1). How-
ever, approximately two-thirds of screened patients
are not suited for the TF approach because of
peripheral arterial disease (2). In addition, the TF
approach is associated with a signiﬁcantly higher rate
of vascular complications when compared with other
approaches (1,3). The available alternatives are
transapical for the Edwards Sapien valve (Edwards
Lifesciences, Irvine, California), subclavian/axillary
for the self-expandable Medtronic CoreValve
ReValving system (CV) (Medtronic, Minneapolis,
Minnesota), and transaortic for both prostheses.
Despite these options, more than 3% of patients with
symptomatic severe aortic stenosis are believed to
have anatomic or physiological features making none
of these approaches feasible (2). We report our ﬁrst-
in-man experience and demonstrate the intra-
procedural safety of the CV percutaneous aortic valve
implantation using the novel retrograde caval-aortic
approach in a subgroup of inoperable patients with
severe aortic stenosis.
All procedures were performed under general
anesthesia and with aseptic technique. Vascular
access in both right and left femoral arteries and veins
was established. Unfractionated heparin was used for
anticoagulation for a target activated clotting time
between 250 to 300 s. A transvenous pacemaker was
placed through the left femoral vein, and a pigtail
catheter was introduced through the right femoralartery. Root aortography was performed during rapid
ventricular pacing with rotational imaging and
computerized tomographic reconstruction in order to
conﬁrm the best aortic valve angulation. Through
standard right femoral vein access, a stiff 0.014-inch
guidewire (Asahi Conﬁanza Pro 12, Abbott Vascular,
Santa Clara, California) inside a 0.035-inch wire con-
verter (PiggyBack, Vascular Solutions, Minneapolis,
Minnesota) was loaded in a Quick-Cross catheter
(Spectranetics, Colorado Springs, Colorado) inside a
5-F Cobra catheter (Terumo, Somerset, New Jersey)
(Figure 1). The distal end of the Conﬁanza Pro 12
guidewire was connected to the cautery set in cut
mode at 50 to 70 W. A vascular EV3 GooseNeck snare
(Covidien, Plymouth, Minnesota) was positioned in
the distal aorta and was used to capture the guidewire
from the vena cava. Conﬁrmation of the orientation
was performed using 15 right anterior oblique and
70 left anterior oblique views at the infrarenal level
with the least amount of calciﬁcation. Once the entire
system was in position, and with the guidewire
pointing to the snare in the aorta, the cautery was
turned on, and the wire was advanced from the
inferior vena cava to the distal aorta through the
lumen of the snare. The wire was then captured in the
snare and advanced to the ascending aortic curva-
ture; the PiggyBack wire was advanced loaded onto a
0.035-inch Quick-Cross catheter. Once in the aortic
arch, the PiggyBack converter and the Conﬁanza Pro
12 guidewire were removed, and the 0.35-inch Quick-
Cross catheter was left in the aortic arch to allow the
exchange of a 0.035-inch Amplatz Super Stiff guide-
wire (Boston Scientiﬁc, Natick, Massachusetts). An
18-F 40-cm Cook Introducer Sheath (Cook Medical,
Bloomington, Indiana) was introduced from the
venous access connecting the femoral vein to the
aorta. The self-expanding CV, mounted in the cath-
eter system, was then advanced to the left ventricular
outﬂow tract to be deployed using the standard
technique. Closure of the aorto-caval ﬁstula was
completed with an Amplatzer Muscular VSD Occluder
(St. Jude Medical, St. Paul, Minnesota). Arterial he-
mostasis was achieved using either manual pressure
or a vascular closure device: Angio-Seal (St. Jude
Medical) or Proglide (Abbott Vascular).
We successfully performed TAVR with caval-aortic
access in 4 patients with a mean age of 81.5  8.5
years (3 women and 1 man), mean Society of Thoracic
Surgeons predicted risk of mortality of 8  4.8%, and
FIGURE 1 Procedural Steps
(A) Venography and aortography before the procedure; (B) Conﬁanza Pro 12 guidewire entering the snare in the aorta; (C) wire captured in the
snare and advanced to the ascending aortic curvature; (D) 18-F introducer sheath introduced from the venous access connecting femoral vein to
aorta; (E and F) Medtronic CoreValve ReValving catheter system advanced to the left ventricular outﬂow tract; (G and H) valve deployment;
and (I) closure of the caval-aortic ﬁstula with the Amplatzer Muscular VSD Occluder device.
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1076mean logistic EuroSCORE of 11  5.8%. All patients
had severe symptomatic aortic stenosis and were
deemed inoperable by cardiac surgeons. All patients
had peripheral arterial disease and contraindications
for both transaortic and subclavian/transaxillary ac-
cess. Valve sizes were 26, 29, and 31 mm (2 patients).
One patient required permanent pacemaker place-
ment. There were no other complications per Valve
Academic Research Consortium criteria (4). The mean
New York Heart Association functional class
improved from 3.5 to 1.25, and the mean aortic valve
area increased from 0.46 to 2.0 cm2. At 6 months
follow-up, all patients were free from rehospitaliza-
tion and noted a signiﬁcant improvement in func-
tional capacity.
Caval-aortic approach was recently described by
Halabi et al. (5) in 14 swine in which access to the
abdominal aorta was gained via the femoral vein or
inferior vena cava. In that report, the caval-aortic
tracts were created by energizing a coronary guide-
wire with an electrosurgery unit, and the tracts wereclosed using Amplatzer Duct occluders (St. Jude
Medical) or Memopart VSD occluders (Lepu Medical,
Shanghai, China) (5). This approach has also been
described in humans with the Edwards Sapien valve;
however, this option has not been explored for CV (6).
This rapid and uncomplicated novel technique in-
corporates advantages of both venous and arterial
approaches without the need of a transseptal punc-
ture and prevents femoral arterial complications. The
more compliant and distensible veins can accommo-
date larger catheter sheaths, thus avoiding any iliofe-
moral arterial complications; the caval-aortic ﬁstulas
did not seem to be acutely life threatening and could
easily be closed with the currently available devices
(5). The operators should therefore be mindful of
the caval-aortic approach, especially for a subgroup
of patients with no arterial access because of small-
caliber, tortuous, calciﬁc, or otherwise obstructed
iliofemoral arteries. Prospective assessment of the
safety and efﬁcacy of this approach with TAVR war-
rants further study with a larger number of patients.
FIGURE 1 Tendyne Mitral Prosthesis
(A) Top view. (B) Side view. The apical tether is secured at the apex after standard
transapical access closure. A 32-F sheath is currently used for its delivery.
FIGURE 2 Deployment of the Tendyne Mitral Prosthesis in Patient 1 and in Patient 2
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First-in-Human Off-Pump
Transcatheter Mitral Valve
Replacement(A–C) Patient 1. (A) Two-dimensional (2D) color Doppler transesophageal echocardi-
ography (TEE) in the 2-chamber view at baseline showing an eccentric jet of severe
mitral regurgitation (MR). (B) End-systolic left ventriculogram pre-implant showing a
fully opaciﬁed left atrium (LA), consistent with severe MR. (C) End-systolic left
ventriculogram post-implant showing lack of MR. (D–F) Patient 2. (D) 2D TEE at
baseline in patient 2 showing an eccentric jet of severe MR. (E) End-systolic left
ventriculogram pre-implant showing a fully opaciﬁed LA, consistent with severe MR.
(F) End-systolic left ventriculogram post-implant showing mild MR. It was
subsequently determined that the MR was paravalvular and originated from the in-
folding of the atrial cuff of the prosthesis (refer to Figure 4).Transcatheter mitral valve replacement (TMVR) faces
signiﬁcant challenges arising from the heterogeneous
pathology of the mitral valve and the anatomic
complexity of the mitral annulus, leaﬂets, and sub-
valvular apparatus (1,2). The Tendyne mitral pros-
thesis (Tendyne Holdings, Roseville, Minnesota) is a
fully retrievable, apically tethered trileaﬂet porcine
pericardial valve sewn onto a nitinol frame (Figure 1).U.S. Food and Drug Administration Export Permit and
international regulatory approvals were obtained
before the study. The protocol was approved by the
National Ethics Committee of Paraguay. Informed
consent was obtained from 2 patients with severe
mitral regurgitation (MR). The patients agreed to have
the Tendyne valve implanted and observed for up to 2
h before proceeding with conventional mitral valve
surgery.
On February 19, 2013, TMVR was performed in
a 57-year-old man with severe MR secondary to
degenerative mitral valve disease. At a later date,
TMVR was also performed in a 55-year-old woman
with severe MR and combined rheumatic and
